For instance, a sub-study of the ENGAGE-AF-TIMI 48 trial demonstrated that patients with the CYP2C9 and VKORC1 variants can benefit more from edoxaban compared to warfarin [113, 114]. This evidence concerns the gene CYP2C9 and atrial fibrillation.